Literature DB >> 30661356

Native Reversed-Phase Liquid Chromatography: A Technique for LCMS of Intact Antibody-Drug Conjugates.

Tse-Hong Chen1, Yun Yang1, Zhaorui Zhang2, Cexiong Fu2, Qunying Zhang2, Jon D Williams3, Mary J Wirth1.   

Abstract

The synthesis of antibody-drug conjugates (ADCs) using the interchain cysteines of the antibody inherently gives a mixture of proteins with varying drug-to-antibody ratio. The drug distribution profiles of ADCs are routinely characterized by hydrophobic interaction chromatography (HIC). Because HIC is not in-line compatible with mass spectrometry (MS) due to the high salt levels, it is laborious to identify the constituents of HIC peaks. An MS-compatible alternative to HIC is reported here: native reversed phase liquid chromatography (nRPLC). This novel technique employs a mobile phase 50 mM ammonium acetate for high sensitivity in MS and elution with a gradient of water/isopropanol. The key to the enhancement is a bonded phase giving weaker drug-surface interactions compared to the noncovalent interactions holding the antibody-drug conjugates together. The hydrophobicity of the bonded phase is varied, and the least hydrophobic bonded phase in the series, poly(methyl methacrylate), is found to resolve the intact constituents of a model ADC (Ab095-PZ) and a commercial ADC (brentuximab vedotin) under the MS-compatible conditions. The nRPLC-MS data show that all species, ranging from drug-to-antibody ratios of 1 to 8, remained intact in the column. Another desired advantage of the nRPLC is the ability of resolving multiple positional isomers of ADC that are not well-resolved in other chromatographic modes. This supports the premise that lower hydrophobicity of the bonded phase is the key to enabling online nRPLC-MS analysis of antibody-drug conjugates.

Entities:  

Year:  2019        PMID: 30661356      PMCID: PMC6727645          DOI: 10.1021/acs.analchem.8b04699

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  33 in total

Review 1.  Hydrophobic interaction chromatography of proteins.

Authors:  J A Queiroz; C T Tomaz; J M Cabral
Journal:  J Biotechnol       Date:  2001-05-04       Impact factor: 3.307

2.  Hydrophobic interaction chromatography of proteins. I. Comparison of selectivity.

Authors:  Christine Machold; Karin Deinhofer; Rainer Hahn; Alois Jungbauer
Journal:  J Chromatogr A       Date:  2002-09-27       Impact factor: 4.759

3.  Evaluation of selectivity changes in HIC systems using a preferential interaction based analysis.

Authors:  Fang Xia; Deepak Nagrath; Shekhar Garde; Steven M Cramer
Journal:  Biotechnol Bioeng       Date:  2004-08-05       Impact factor: 4.530

4.  Antibody-drug conjugates for cancer: poised to deliver?

Authors:  Bethan Hughes
Journal:  Nat Rev Drug Discov       Date:  2010-09       Impact factor: 84.694

5.  Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides.

Authors:  Michael M C Sun; Kevin S Beam; Charles G Cerveny; Kevin J Hamblett; Richard S Blackmore; Michael Y Torgov; Felicia G M Handley; Nathan C Ihle; Peter D Senter; Stephen C Alley
Journal:  Bioconjug Chem       Date:  2005 Sep-Oct       Impact factor: 4.774

6.  Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate.

Authors:  Kevin J Hamblett; Peter D Senter; Dana F Chace; Michael M C Sun; Joel Lenox; Charles G Cerveny; Kim M Kissler; Starr X Bernhardt; Anastasia K Kopcha; Roger F Zabinski; Damon L Meyer; Joseph A Francisco
Journal:  Clin Cancer Res       Date:  2004-10-15       Impact factor: 12.531

7.  Hydrophobic interaction chromatography of proteins. II. Solution thermodynamic properties as a determinant of retention.

Authors:  Brian C S To; Abraham M Lenhoff
Journal:  J Chromatogr A       Date:  2007-01-04       Impact factor: 4.759

Review 8.  Theory and use of hydrophobic interaction chromatography in protein purification applications.

Authors:  Justin T McCue
Journal:  Methods Enzymol       Date:  2009       Impact factor: 1.600

9.  Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats.

Authors:  C Andrew Boswell; Eduardo E Mundo; Crystal Zhang; Daniela Bumbaca; Nicole R Valle; Katherine R Kozak; Aimee Fourie; Josefa Chuh; Neelima Koppada; Ola Saad; Herman Gill; Ben-Quan Shen; Bonnee Rubinfeld; Jay Tibbitts; Surinder Kaur; Frank-Peter Theil; Paul J Fielder; Leslie A Khawli; Kedan Lin
Journal:  Bioconjug Chem       Date:  2011-10-03       Impact factor: 4.774

10.  In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.

Authors:  Russell J Sanderson; Michelle A Hering; Stephanie F James; Michael M C Sun; Svetlana O Doronina; Anthony W Siadak; Peter D Senter; Alan F Wahl
Journal:  Clin Cancer Res       Date:  2005-01-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.